Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol.

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Corrigendum: Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram

Provisionally accepted
  • 1Massachusetts General Hospital, Boston, United States
  • 2Tongji Hospital, School of Medicine, Tongji University, Shanghai, China

The final, formatted version of the article will be published soon.

H, Cai L, Zhang L, Tanabe KK and Wang X (2022) Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram. Front. Oncol. 12:913736. doi: 10.3389/fonc.2022.913736 In the published article, there was an error in Figure 2E as published. Some of the sphere images were unintentionally duplicated during the preparation process. The corrected Figure 2E and its caption appear below.

Keywords: Copper, Disulfiram, ERK pathway, Hepatic cancer stem cells, Sorafenib

Received: 20 Dec 2025; Accepted: 03 Feb 2026.

Copyright: © 2026 Zhang, Wang, Fuchs, Guo, Drum, Erstad, Shi, DeLeo, Zheng, Cai, Zhang, Tanabe and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xinhui Wang

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.